Start-up Avro Life Sciences is set to launch patches that deliver drugs to patients using a polymer developed by founders Shak Lakhani and Keean Sarani. The company has won seed backing from three years, Susa Ventures, Garage Capital, Heuristic Capital, Embark Ventures, Uphonest Capital and Buckley Endeavours along with individual investors and has raised $2.2m. Avro’s first product is a patch that treats seasonal allergies with antihistamine Loratadine. Future patches could treat cardiac health and neurodegenerative diseases and could revive drugs abandoned because oral delivery was too difficult. It could also cut pharmaceutical companies’ costs.
Start-up Avro Life Sciences is set to launch patches that deliver drugs to patients using a polymer developed by founders Shak Lakhani and Keean Sarani. The company has won seed backing from Fifty Years, Susa Ventures, Garage Capital, Heuristic Capital, Embark Ventures, Uphonest Capital and Buckley Endeavours along with individual investors and has raised $2.2m. Avro’s first product is a patch that treats seasonal allergies with antihistamine Loratadine. Future patches could treat cardiac health and neurodegenerative diseases and could revive drugs abandoned because oral delivery was too difficult. It could also cut pharmaceutical companies’ costs.